Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | PLG | P00747 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | PLAT | P00750 | 1/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
| ▸ | MELK | Q14680 | 2/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.52 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18491400 | 0.98 | ITGB3 (0.56) | F2PLGPLAUPLATKLKB1 | |
| SCHEMBL1045965 | 0.94 | MELK (0.64) | F2PLGPLAUPLATKLKB1 | |
| SCHEMBL17797703 | 0.91 | NPC1 (0.50) | F2PLGPLAUPLATKLKB1 | |
| SCHEMBL12501320 | 0.86 | ITGB3 (0.58) | ITGB3ITGA2B | |
| SCHEMBL7903531 | 0.86 | F2 (0.56) | F2PLGPLAUPLATKLKB1 | |
| Hydrochloric Acid SCHEMBL31174279 | 0.84 | F2 (0.55) | F2PLGPLAUPLATKLKB1 | |
| SCHEMBL17797501 | 0.84 | MELK (0.54) | MELKITGB3ITGA2BSLC2A1ITGA2 | |
| Hydrochloric Acid SCHEMBL1188323 | 0.84 | NPC1 (0.65) | F2PLGPLAUPLATKLKB1 | |
| SCHEMBL8197860 | 0.84 | MELK (0.68) | F2PLGPLAUPLATKLKB1 | |
| SCHEMBL3003689 | 0.83 | F2 (0.54) | F2PLGPLAUPLATKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| EP-4103182-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Salk Institute for Biological Studies (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021163629-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-08-19 | — | — | WO | disclosed |
| US-8741890-B2 | Substituted amides, manufacturing and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| CN-102369195-B | Autotaxin inhibitors | MERCK PATENT GMBH | 2014-04-16 | — | — | CN | disclosed |
| EP-2220079-A2 | SUBSTITUTED AMIDES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009063028-A2 | SUBSTITUTED AMIDES, MANUFACTURING AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | ULK2, ULK1, ULK3 | F2 4413/4885PLG 2384/4885PLAU 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.